Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
June 03 2023 - 7:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that new data on DecisionDx®-Melanoma and
DecisionDx®-UM will be shared during the 2023 American
Society of Clinical Oncology (ASCO) Annual Meeting, taking place
June 2-6. DecisionDx-Melanoma is the Company’s genomic
risk-stratification test for patients with cutaneous melanoma, and
DecisionDx-UM is the standard of care in the management of newly
diagnosed uveal melanoma in the majority of ocular oncology
practices in the United States.
Details regarding Castle’s accepted abstracts are as
follows:
DecisionDx-Melanoma Abstract #6601: Integrating
the 31-gene expression profile test into clinical decision-making
to guide risk-aligned care decisions for patients with stage I-III
cutaneous melanoma: NCI-SEER Analysis. First Author: David Hyams,
M.D., F.A.C.S., director of Desert Surgical Oncology in Rancho
Mirage, California Session Type: Poster Session Poster Bd #: 93
Session Title: Health Services Research and Quality Improvement
Date & Time: Saturday, June 3, 1:15-4:15 p.m. Central time
The abstract can be viewed here.
DecisionDx-UM Abstract #e21574: Long-term outcomes
in a population-based cohort of 2,967 uveal melanoma patients
clinically tested with the 15-gene expression profile: A
collaborative study with the National Cancer Institute (NCI)
Surveillance, Epidemiology, and End Results (SEER) Program
Registries. Session Type: Publication Only Session Title:
Publication Only: Melanoma/Skin Cancers
The abstract can be viewed here.
About DecisionDx-Melanoma
DecisionDx-Melanoma is a gene expression profile risk
stratification test. It is designed to inform two clinical
questions in the management of cutaneous melanoma: a patient’s
individual risk of sentinel lymph node (SLN) positivity and a
patient's personal risk of melanoma recurrence and/or metastasis.
By integrating tumor biology with clinical and pathologic factors
using a validated proprietary algorithm, DecisionDx-Melanoma is
designed to provide a comprehensive and clinically actionable
result to guide risk-aligned patient care. DecisionDx-Melanoma has
been shown to be associated with improved patient survival and has
been studied in more than 10,000 patient samples.
DecisionDx-Melanoma’s clinical value is supported by more than 40
peer-reviewed and published studies, providing confidence in
disease management plans that incorporate the test’s results.
Through March 31, 2023, DecisionDx-Melanoma has been ordered more
than 128,000 times for patients diagnosed with cutaneous
melanoma.
About DecisionDx®-UM
DecisionDx-UM is Castle Biosciences’ 15-gene expression profile
(GEP) test that uses an individual patient’s tumor biology to
predict individual risk of metastasis in patients with uveal
melanoma. DecisionDx-UM is the standard of care in the management
of newly diagnosed uveal melanoma in the majority of ocular
oncology practices in the United States. Since 2009, the American
Joint Committee on Cancer (AJCC; v7 and v8) Staging Manual for UM
has specifically identified the GEP test as a prognostic factor
that is recommended for collection as a part of clinical care.
Further, the National Comprehensive Cancer Network (NCCN)
guidelines for uveal melanoma include the DecisionDx-UM test result
as a prognostic method for determining risk of metastasis and
recommended differential surveillance regimens based on a Class 1A,
1B, and 2 result. DecisionDx-UM is the only prognostic test for
uveal melanoma that has been validated in prospective, multi-center
studies, and it has been shown to be a superior predictor of
metastasis compared to other prognostic factors, such as chromosome
3 status, mutational status, AJCC stage and cell type. It is
estimated that nearly 8 in 10 patients diagnosed with uveal
melanoma in the U.S. receive the DecisionDx-UM test as part of
their diagnostic workup.
More information about Castle’s tests can be found at
www.CastleTestInfo.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230603005008/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jul 2023 to Jul 2024